Lung Cancer

The FDA has granted a breakthrough therapy designation to the third-generation EGFR TKI BI-1482694 as a potential treatment for patients with EGFR T790M-positive non–small cell lung cancer.

Frontline treatment with afatinib reduced the risk of progression or death by 27% compared with gefitinib for patients with EGFR-mutant non–small cell lung cancer.

Treatment with pembrolizumab reduced the risk of death by 29% compared with docetaxel for patients with PD-L1-positive non–small cell lung cancer.

The FDA has extended the review period for rociletinib in patients with EGFR T790M-positive non–small cell lung cancer by 3 months, to allow ample time to review additional data.

The FDA has granted an accelerated approval to alectinib as a treatment for patients with metastatic ALK-positive non–small cell lung cancer following progression on crizotinib.

The FDA has granted a priority review to crizotinib as a treatment for patients with ROS1-positive metastatic non–small cell lung cancer.

Gregory Riely, MD Medical Oncologist, Vice Chair, Clinical Trials Office, Department of Medicine, Memorial Sloan Kettering, discusses the benefits and challenges of using next-generation sequencing to identify mutations in lung cancer.

As the class of agents targeting the PD-1/PD-L1 pathway expands in non–small cell lung cancer, so does the potential population of patients who would be candidates for the groundbreaking immunotherapy.

Suresh Ramalingam, MD, discusses the evolving role of checkpoint inhibitors in lung cancer and what challenges still remain.

Naiyer A. Rizvi, MD, discusses results of a study looking at the combination of the anti-PD-L1 immune checkpoint inhibitor durvalumab (MEDI4736) with the anti–CTLA-4 monoclonal antibody tremelimumab in patients with advanced non–small cell lung cancer.

dward Garon, MD, assistant professor of Medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at University of California, Los Angeles, discusses incorporating immunotherapies into the treatment of patients with lung cancer.

The efforts of the Kentucky LEADS Collaborative offer a unique opportunity to change the face of lung cancer in Kentucky by harnessing new lung cancer care and control strategies.

The FDA has approved necitumumab in combination with gemcitabine and cisplatin for the first-line treatment of patients with locally advanced or metastatic squamous non–small cell lung cancer.

The FDA has requested additional clinical trial data to support a new drug application for rociletinib as a potential therapy for pretreated patients with EGFR T790M mutation-positive NSCLC.

The FDA has granted an accelerated approval to osimertinib for patients with advanced EGFR T790M mutation positive non–small cell lung cancer following prior therapy on a prior EGFR TKI.

Thomas J. Lynch, MD, CEO, chairman, Massachusetts General Hospital Physicians Organization, discusses targeting EGFR mutation subtypes as a frontline treatment for lung cancer.

Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses how to define resistance to EGFR-inhibitors in lung cancer.

Roman Perez-Soler, MD, expanded on the importance of PD-1 inhibitors for all patients and the role of biomarker testing.

Benjamin P. Levy, MD, attending physician, Department of Medicine, Mount Sinai Beth Israel and Mount Sinai St. Luke's Roosevelt, Mount Sinai Health System, discusses EGFR TKIs for the treatment of patients with lung cancer.

The latest FDA approval for nivolumab in non–small cell lung cancer means that the drug potentially can be administered to any patient in the second-line setting, regardless of tumor histology or PD-L1 expression level.

Treatment of patients with non–small cell lung cancer should be based on the identification of rare molecular targets such as BRAF, RET, ROS1, and MET versus clinical characteristics.